WuXi XDC Cayman, Inc. · HKEX:2268

WuXi XDC Cayman — WuXi XDC — Technical Presentation (July 2024)

21 slides from WuXi XDC Cayman's technical presentation, July 2024

  1. Slide 1: Antibody–Oligonucleotide Conjugates Landscape and WuXi XDC's Capabilities in AOCs

    Antibody–Oligonucleotide Conjugates Landscape and WuXi XDC’s Capabilities in AOCs WuXi XDC Jul, 2024

  2. Slide 2: Antibody–Oligonucleotide Conjugates (AOC) Landscape

    Antibody–Oligonucleotide Conjugates (AOC) Landscape

  3. Slide 3: What are Antibody–Oligonucleotide Conjugates?

    What are Antibody–Oligonucleotide Conjugates? ❑ Antibody–oligonucleotide conjugates (AOCs) combine the high precision of small interfering RNA (siRNA) and anti-sense oligonucleotides (ASO) with the deliverability of antibodies, thus synergizing the advantages of both technologies. ❑ Although siRNA a

  4. Slide 4: Major Advantages of AOCs

    Major Advantages of AOCs As compared to oligonucleotides • Better selectivity • Better stability • Better transmembrane properties As compared to LNP • Simpler components • Better targeting As compared to GalNAc • More diverse targets to select Source of the picture regarding AOC structure: Wikipedi

  5. Slide 5: Competitive landscape of AOC field

    Competitive landscape of AOC field Preclinical Phase 1/2 Phase 2 Phase 3 30+ AOCs 4 AOCs 1 AOC 1 AOC Others DMD; FSHD; Cancer; Cardiovascular Diseases; Metabolic Myotonic dystrophy type 1 (DM1); Duchenne Muscular Indications: Disorders; Atrophy; Pompe Disease; Spinal muscular atrophy; Dystrophy (DMD

  6. Slide 6: Selected AOCs in Clinical Trials

    Selected AOCs in Clinical Trials Antibody Therapeutic Drug Sponsor Tissue target Indication Status properties payload AOC 1001 Avidity TfR1-targed mAb DMPK siRNA Muscle DM1 Phase 3 Exon-44-skipping AOC 1044 Avidity TfR1-targed mAb Muscle DMD Phase 2 PMO AOC 1020 Avidity TfR1-targed mAb DUX4 siRNA Mu

  7. Slide 7: Avidity Biosciences: a Pioneer Company in AOCs

    Avidity Biosciences: a Pioneer Company in AOCs o Avidity’s successful pivotal clinical trial proved finally the concept of AOCs o Initiated in May 2024 global Phase 3 HARBOR™ trial of AOC 1001 o Avidity and BMS signed in November 2023 a $2.3bn deal for cardiovascular targets. Source: official websit

  8. Slide 8: General Methods to Conjugate Oligonucleotides

    General Methods to Conjugate Oligonucleotides Random Conjugations Site Specific Conjugations Cysteine ThiomAb Nanobody V DAR2 H H BsAb Lysine DAR1

  9. Slide 9: WuXi XDC's Capabilities in AOCs and Beyond

    WuXi XDC’s Capabilities in AOCs and Beyond

  10. Slide 10: WuXi XDC Has Extensive Experience On Diverse AOCs

    WuXi XDC Has Extensive Experience On Diverse AOCs Delivered 400+ AOC Products Scale: 1mg~100g Conjugation Multiple Conjugation methods Comprehensive Purification / Characterization methods

  11. Slide 11: Case 1: One Conjugation to Get Two AOCs With Two Different DAR values

    Case 1: One Conjugation to Get Two AOCs With Two Different DAR values Simultaneously for Further Evaluation Step 1 Step 2 Deblocking Partial Conjugation with Oligo DAR2 + Separation/Purification Thiomab Thiomab NEM DAR1 ❑ This project was at discovery stage, and the client had to assess which DAR va

  12. Slide 12: Case 2: Comprehensive Purification Toolbox to Remove Different AOC Impurities

    Case 2: Comprehensive Purification Toolbox to Remove Different AOC Impurities AOC with different oligos have different impurity profiles. Different oligos AOC HPLC Profile of crude High purity products Comprehensive AOC Purification Toolbox

  13. Slide 13: Case 3: A Finished Integrated AOC Discovery Project

    Case 3: A Finished Integrated AOC Discovery Project Discussion for the AOC generation for in Larger scale AOC NHP tox study Lead Selection for conjugation strategy Vitro and in Vivo preparation CMC studies • Multiple conjugation • 15+ AOCs at mg scale • 2 AOCs at 4g scale • NHP tox completed • One L

  14. Slide 14: WuXi XDC's Capabilities in broader Bioconjugates

    WuXi XDC’s Capabilities in broader Bioconjugates

  15. Slide 15: WuXi XDC Integrated One-Stop CRDMO Service

    WuXi XDC Integrated One-Stop CRDMO Service Antibody Discovery Conjugation Research CMC Development IND Filing Commercial Manufacturing Discovery Process Development Payload & Linker Manufacturing An integrated ADC Discovery Industry-leading Process Payload-Linker Integrated Service o Bio-conjugate M

  16. Slide 16: WuXi XDC's Expertise is Much More Than in AOCs

    WuXi XDC’s Expertise is Much More Than in AOCs Bioconjugate Modules Native mAb: IgG1, IgG2, IgG4 Antibody Engineered mAb: ThiomAb, NNAA THIOMAB™ NNAA Enzyme-assisted ADC Bi-specific mAb, Nanobody etc. Small molecule linker-payloads LP (Highly potent & non-potent), Dual payloads Radioisotope chelator

  17. Slide 17: Integrated ADC/Bioconjugate Discovery Service from Concept to PCC

    Integrated ADC/Bioconjugate Discovery Service from Concept to PCC Binding, Internalization, In Antibody lead • Payload-linker library: vcMMAE, MC- vitro killing, Plasma/Serum identification, MMAF, SMCC-DM1, SPBD-DM4, GGFG- Stability, Metabolite ID optimization and DXd, CL2A-SN38, Tesirine, etc. prod

  18. Slide 18: WuXi XDC's Proprietary Technology- WuXiDAR4

    WuXi XDC’s Proprietary Technology- WuXiDAR4TM D4 D2 D0 D6 D8 Highly Compatible with Meet clients’ Simple CMC and homogenous ADC native mAb diversified needs Cost Saving • ≥ 65% of • No antibody • Compatible with • Simple conjugation a single conjugated engineering common linker- process. species wit

  19. Slide 19: Contact Information

    Contact Information You are welcome to contact us via the following email or link if you are interested in our company’s service in discovery, development and manufacturing of AOCs and other conjugates. Email:[email protected] https://wuxixdc.com/contact-us/

  20. Slide 20: Our Mission

    Our Mission To accelerate and transform the discovery, development and manufacturing of bioconjugates through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide.

  21. Slide 21: Thanks!

    STRONGER AS WuxXi XDC - Your One-Stop Antibody Drug Conjugate (ADC) Development Solution Source: Platform: Team: + Payload-linker + ADCDiscovery __« Service & Support + Antibody + ADC Technology + Product Management Platform + Conjugate + CMC Development + Project Accountability +44 + Drug Product »

WuXi XDC — Technical Presentation (July 2024) on 6ix